Moreover, Xu et al. [50] showed that the constitutive SREBP1-mediated activation of the lipogenic pathway is a key mediator of gefitinib-acquired resistance in EGFR mutant lung cancer, and targeting SREBP1 with fatostatin restored gefitinib sensitivity in resistant NSCLC in both in vitro and in vivo models. This evidence concerns the gene SREBF1 and lung cancer.